Implication of the nutritional and nonnutritional factors in the context of preservation of cognitive performance in patients with dementia/depression and Alzheimer disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 7, 2013, Pages 660-670

  Aliev, Gjumrakch ^a,b   Ashraf, Ghulam Md ^c   Kaminsky, Yury G ^d   Sheikh, Ishfaq Ahmed ^c   Sudakov, Sergey K ^e   Yakhno, Nikolay N ^f   Benberin, Valery V ^g   Bachurin, Sergey O ^h  

^a GALLY International Biomedical Research Consulting LLC   (United States)

^b University of Atlanta   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^e INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^f I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^g Hosp of the Medical Center of the President's Affairs Administration of the Republic of Kazakhstan   (Kazakhstan)

^h INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

Alzheimer disease; cardio and cerebrovascular disease; dementia; depression; integrative treatment; memory training; naturalistic study; nonpharmacological interventions; nutrition; physical exercises

Indexed keywords

AC 1202; ANTIDEPRESSANT AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DULOXETINE; ESCITALOPRAM; MEMANTINE; MITOCHONDRIAL DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NUTRACEUTICAL; OMEGA 3 ACID ETHYL ESTER; RIVASTIGMINE; VITAMIN D;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; COGNITION; COMORBIDITY; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DEPRESSION; EMOTION; EXERCISE; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPROTECTION; NONHUMAN; NUTRITION; OXIDATIVE STRESS; PHYSICAL ACTIVITY; REVIEW; TRAUMATIC BRAIN INJURY; VITAMIN D DEFICIENCY;

ALZHEIMER DISEASE; CARDIO- AND CEREBROVASCULAR DISEASE; DEMENTIA; DEPRESSION; INTEGRATIVE TREATMENT; MEMORY TRAINING; NATURALISTIC STUDY; NONPHARMACOLOGICAL INTERVENTIONS; NUTRITION; PHYSICAL EXERCISES;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DEPRESSION; DIETARY SUPPLEMENTS; HUMANS; VITAMINS;

EID: 84887891918     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513504614     Document Type: Review

References (61)

1. Aliev G. Oxidative stress induced-metabolic imbalance, mitochondrial failure, and cellular hypoperfusion as primary pathogenetic factors for the development of Alzheimer disease which can be used as a alternate and successful drug treatment strategy: past, present and future. CNS Neurol Disord Drug Targets. 2011 ; 10 (2). 147-148
2. Golde TE. Disease modifying therapy for AD?. J Neurochem. 2006 ; 99 (3). 689-707
3. Aliev G The Role of Oxidative Stress, Mitochondria Failure, and Cellular Hypoperfusion in the Context of Alzheimer Disease: Past, Present and Future. Monograph Book. New York: Nova Science Publishers, Inc ; 2013: 1-426.
4. Vančová O, Bačiak L, Kašparová S, et al. In vivo and in vitro assessment of brain bioenergetics in aging rats. J Cell Mol Med. 2010 ; 14 (11). 2667-2674
5. Horecký J, Baciak L, Kasparová S, Pacheco G, Aliev G, Vancová O. Minimally invasive surgical approach for three-vessel occlusion as a model of vascular dementia in the rat-brain bioenergetics assay. J Neurol Sci. 2009 ; 283 (1-2). 178-181
6. Aliev G, Gasimov E, Obrenovich ME, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease. Vasc Health Risk Manag. 2008 ; 4 (3). 721-730
7. Pivi GA, Bertolucci PH, Schultz RR. Nutrition in severe dementia. Curr Gerontol Geriatr Res. 2012 ; 983056: 1-7
8. Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G. Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Demen. 2005 ; 20 (1). 21-26
9. Bragin V, Chemodanova M, Bragin I, et al. A 60-month follow-up of a naturalistic study of integrative treatment for real-life geriatric patients with depression, dementia and multiple chronic illnesses. Open J Psychiatry. 2012 ; 2 (2). 129-140
10. Aliev G, Li Y, Palacios HH, Obrenovich ME. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent Pat Cardiovasc Drug Discov. 2011 ; 6 (3). 222-241
11. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007 ; 80 (spec 2). S160 - S167
12. Maksimovich IV. Vascular factors in Alzheimer's disease. Health. 2012 ; 4 (9A). 735-742
13. Sundström T, Elgh E, Larsson A, Näsman B, Nyberg L, Riklund KA. Memory-provoked rCBF-SPECT as a diagnostic tool in Alzheimer's disease?. Eur J Nucl Med Mol Imaging. 2006 ; 33 (1). 73-80
14. Kitabayashi Y, Ueda H, Tsuchida H, et al. Relationship between regional cerebral blood flow and verbal fluency in Alzheimer's disease. Psychiatry Clin Neurosci. 2001 ; 55 (5). 459-463
15. Nagahama Y, Nabatame H, Okina T, et al. Cerebral correlates of the progression rate of the cognitive decline in probable Alzheimer's disease. Eur Neurol. 2003 ; 50 (1). 1-9
16. Silverman DH, Mosconi L, Ercoli L, Chen W, Small GW. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med. 2008 ; 38 (4). 251-261
17. Mehta L, Thomas S. The role of PET in dementia diagnosis and treatment. Appl Radiol. 2012 ; 41 (5). 8-15
18. van Halteren-van Tilborg IA, Scherder EJ, Hulstijn W. Motor-skill learning in Alzheimer's disease: a review with an eye to the clinical practice. Neuropsychol Rev. 2007 ; 17 (3). 203-212
19. Grady CL, Haxby JV, Horwitz B, et al. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging. 1993 ; 14 (1). 35-44
20. Mozolic JL, Hayasaka S, Laurienti PJ. A cognitive training intervention increases resting cerebral blood flow in healthy older adults. Front Hum Neurosci. 2010 ; 4: 16
21. Kawashima R. Mental exercises for cognitive function: clinical evidence. J Prev Med Public Health. 2013 ; 46 (suppl 1). S22 - S27
22. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008 ; 300 (9). 1027-1037
23. de la Torre JC, Aliev G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab. 2005 ; 25 (6). 663-672
24. Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc. 2011 ; 86 (9). 876-884
25. Bragin V How to Activate Your Brain. Bloomington, IN: Authorhouse ; 2007 :
26. Roland PE, Meyer E, Shibasaki T, Yamamoto YL, Thompson CJ. Regional cerebral blood flow changes in cortex and basal ganglia during voluntary movements in normal human volunteers. J Neurophysiol. 1982 ; 48 (2). 467-480
27. Khalsa DS, Amen D, Hanks C, Money N, Newberg A. Cerebral blood flow changes during chanting meditation. Nucl Med Commun. 2009 ; 30 (12). 956-961
28. Stafstrom CE, Rho JM. The Ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012 ; 3 (59). 1-5
29. McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J. 2008 ; 22 (4). 982-1001
30. McCann JC, Ames BN. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?. Am J Clin Nutr. 2009 ; 90 (4). 889-907
31. Aliev G, Liu J, Shenk JC, et al. Neuronal mitochondrial amelioration by feeding acetyl-l-carnitine and lipoic acid to aged rats. J Cell Mol Med. 2009 ; 13 (2). 320-333
32. Ames BN. Increasing longevity by tuning up metabolism. Proc Natl Acad Sci USA. 2006 ; 103 (47). 17589-17594
33. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, Aliev G. The effect of acetyl-l-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci. 2009 ; 283 (1-2). 199-206
34. Remington R, Chan A, Paskavitz J, Shea TB. Efficacy of a vitamin/nutraceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen. 2009 ; 24 (1). 27-33
35. Horecký J, Gvozdjáková A, Kucharská J, et al. Effects of coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. Curr Alzheimer Res. 2011 ; 8 (8). 868-875
36. Mizrahi EH, Jacobsen DW, Debanne SM, et al. Plasma total homocysteine levels, dietary vitamin B6 and folate intake in AD and healthy aging. J Nutr Health Aging. 2003 ; 7 (3). 160-165
37. Mizrahi EH, Bowirrat A, Jacobsen DW, et al. Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. J Neurol Sci. 2004 ; 227 (1). 109-113
38. Pocernich CB, Lange ML, Sultana R, Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr Alzheimer Res. 2011 ; 8 (5). 452-469
39. Kamphuis PJ, Wurtman RJ. Nutrition and Alzheimer's disease: pre-clinical concepts. Danone research-centre for specialised nutrition, Wageningen, The Netherlands. Eur J Neurol.. 2009 ; 16 (1). 12-18
40. Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimers Dis. 1999 ; 1 (4-5). 203-236
41. Perry G, Nunomura A, Raina AK, et al. A metabolic basis for Alzheimer disease. Neurochem Res. 2003 ; 28 (10). 1549-1552
42. Petot GJ, Friedland RP. Lipids, diet and Alzheimer disease: an extended summary. J Neurol Sci. 2004 ; 226 (1-2). 31-33
43. Shea TB, Rogers E, Remington R. Nutrition and dementia: are we asking the right questions?. J Alzheimers Dis. 2012 ; 30 (1). 27-33
44. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. Weight loss in Alzheimer disease. Am J Clin Nutr. 2000 ; 71 (2). 637S - 642S
45. Herzig KH, Purhonen AK, Räsänen KM, et al. Fecal pancreatic elastase-1 levels in older individuals without known gastrointestinal diseases or diabetes mellitus. BMC Geriatr. 2011 ; 11: 4
46. Hardt PD, Ewald N. Exocrine pancreatic insufficiency in diabetes mellitus: a complication of diabetic neuropathy or a different type of diabetes?. Exp Diabetes Res. 2011 ; 2011: 761950
47. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 ; 22 (3). 209-221
48. Nobili F, Vitali P, Canfora M, et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol. 2002 ; 113 (8). 1241-1248
49. Lipczyńska-Łojkowska W, Ryglewicz D, Jedrzejczak T, et al. The effect of Rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years. Neurol Neurochir Pol. 2004 ; 38 (6). 471-481
50. Alcántara-González F, Mendoza-Perez CR, Zaragoza N, et al. Combined administration of cerebrolysin and Donepezil induces plastic changes in prefrontal cortex in aged mice. Synapse. 2012 ; 66 (11). 938-949
51. Kuo MF, Grosch J, Fregni F, Paulus W, Nitsche MA. Focusing effect of acetylcholine on neuroplasticity in the human motor cortex. J Neurosci. 2007 ; 27 (52). 14442-14447
52. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does Donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychiatry. 2005 ; 162 (4). 676-682
53. Wang L, Harms MP, Staggs JM, et al. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Arch Neurol. 2010 ; 67 (1). 99-106
54. Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in DAT subjects. Am J Psychiatry. 2006 ; 163 (12). 2164-2169
55. Hill KD, LoGiudice D, Lautenschlager NT, Said CM, Dodd KJ, Suttanon P. Effectiveness of balance training exercise in people with mild to moderate severity Alzheimer's disease: protocol for a randomized trial. BMC Geriatr. 2009 ; 9: 29
56. Obrenovich ME, Smith MA, Siedlak SL, et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res. 2006 ; 10 (1). 43-56
57. Olazarán J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010 ; 30 (2). 161-178
58. Ruthirakuhan M, Luedke AC, Tam A, Goel A, Kurji A, Garcia A. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. J Aging Res. 2012 ; 2012: 384875
59. Yamagami T, Takayama Y, Maki Y, Yamaguchi H. A randomized controlled trial of brain-activating rehabilitation for elderly participants with dementia in residential care homes. Dement Geriatr Cogn Dis Extra. 2012 ; 2 (1). 372-380
60. Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a vitamin/nutraceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen. 2008 ; 23 (6). 571-585
61. Palacios HH, Yendluri BB, Parvathaneni K, et al. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets. 2011 ; 10 (2). 149-162